The year 1987 witnessed further steps in the transition from conventional chemotherapy to biological compounds for the treatment of cancer. The possibilities of the CSFs as well as the related interleukins (IL-1 and IL-3) are discussed in detail in this edition of the Annual, and represent a landmark in that the major limiting toxicity of conventional chemotherapy, myelosuppression, may become controllable and avoidable. Monoclonal antibodies and growth factor-related strategies are discussed in detail in the sections on biologicals (Chapters 28-34) and Steroid and Peptide hormones and growth factors (Chapter 11). Highlighting the progress in the understanding and clinical application of biologicals is not intended to minimize the substantial progress made in the past year in conventional chemotherapy, - including expanding indications for, and improved results of therapy with, VP-16. Considerable progress has been made in understanding MDR-1 at the biological and clinical levels in the past year (Chapter 9), whilst attention must also be drawn to the drug-related chapters providing important new information.
The year 1987 witnessed further steps in the transition from conventional chemotherapy to biological compounds for the treatment of cancer. The possibilities of the CSFs as well as the related interleukins (IL-1 and IL-3) are discussed in detail in this edition of the Annual, and represent a landmark in that the major limiting toxicity of conventional chemotherapy, myelosuppression, may become controllable and avoidable. Monoclonal antibodies and growth factor-related strategies are discussed in detail in the sections on biologicals (Chapters 28-34) and Steroid and Peptide hormones and growth factors (Chapter 11). Highlighting the progress in the understanding and clinical application of biologicals is not intended to minimize the substantial progress made in the past year in conventional chemotherapy, - including expanding indications for, and improved results of therapy with, VP-16. Considerable progress has been made in understanding MDR-1 at the biological and clinical levels in the past year (Chapter 9), whilst attention must also be drawn to the drug-related chapters providing important new information.
Reihe
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Technology
Zielgruppe
Für höhere Schule und Studium
Für Beruf und Forschung
Maße
ISBN-13
978-0-444-81015-1 (9780444810151)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Klassifikation
I. DRUGS. 1. Antimetabolites (C.J. Allegra et al). 2. Alkylating agents, nitrosoureas and alkyltriazenes (T.A. Connors). 3. Anthracyclines (C.E. Myers). 4. Bleomycins (Y. Muraoka and T. Takita). 5. Mitomycin C (J. Den Hartigh et al). 6. Vinca alkaloids (G. Schwartsmann and R.A. Bender). 7. Podophyllotoxin derivatives VP-16 and VM-26 (M. D'Incalci and S. Garattini). 8. Cisplatin and new platinum analogs (L.A. Zwelling). 9. Multidrug resistance (R.L. Fine). 10. New anticancer agents (G.R. Weiss et al). 11. Steroid and peptide hormones and growth factors (A. Howell and A.E. Wakeling). II. TUMORS. 12. Leukemias and myeloma (P.H. Wiernik). 13. Lymphomas (D.L. Longo and V.T. De Vita Jr). 14. AIDS and related disorders (R. Yarchoan et al). 15. Head and neck cancer (S.G. Taylor IV). 16. Lung cancer (H.H. Hansen and M. Rorth). 17. Upper gastrointestinal tumors (M. Ogawa and T. Taguchi). 18. Cancers of the large bowel, pancreas and hepatobiliary tract (P.V. Woolley III et al). 19. Endocrine tumors (J.J.M. van der Hoeven and H.M. Pinedo). 20. Genitourinary cancer (R.F. Ozols and A. Yagoda). 21. Gynecologic malignancies (J.D. Nash and R.C. Young). 22. Breast cancer (L.C. Hartmann and C.L. Loprinzi). 23. Melanoma (Ph. Rumke). 24. Soft tissue and bone sarcomas (A. Santoro and G. Bonadonna). 25. Brain tumors (M.G. Malkin and W.R. Shapiro). 26. Pediatric tumors (D. Olive et al). 7. Supportive care (M. Markman). III. BIOLOGICAL RESPONSE MODIFIERS. 28. Monoclonal antibodies and immunoconjugates for cancer treatment (R.W. Baldwin et al). 29. Lymphokines and cytokines (J. Wagstaff and C.J. Melief). 30. Biological response modifiers (J.W. Clark). 31. Adoptive cellular therapy (W.J. Urba and D.L. Longo). 32. Immunological monitoring and clinical trials of biological response modifiers (W.J. Urba and M.W. Baseler). 33. Biological effects and clinical applications of human colony stimulating factors (J.L. Gabrilove). 34. Growth and differentiation control (G.E. Francis and C.M. Pinsky). List of abbreviations of drugs. List of abbreviations of chemotherapeutic combinations. List of NSC numbers. Subject index.
